Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association 73rd Scientific Sessions in Chicago, IL. The data suggest that PaQ can reduce known barriers to insulin therapy among people with type 2 diabetes, potentially improving their glycemic control.

24 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Study: Multiple islet autoantibodies in children indicate risk of developing type 1 diabetes

A decade-long JDRF-funded study led by the Institute of Diabetes Research in Helmholtz Zentrum M-nchen, Germany, is providing a deeper understanding of the link between autoantibodies and the risk of developing type 1 diabetes, highlighting the importance of pre-diabetes research into possible preventions for the disease.

20 Jun 2013

Loyola researcher to study role of Vitamin D in women with diabetes and depression

A Loyola University Chicago Niehoff School of Nursing researcher has received a four-year, $1.49 million grant to study whether Vitamin D can improve mood in women with diabetes who are depressed.

20 Jun 2013

GSMA announces first-of-its-kind clinical study for its mHealth Grand Tour

The GSMA today announced a first-of-its-kind clinical study for its mHealth Grand Tour in September 2013, which is designed to raise awareness of diabetes and promote the development and delivery of mHealth solutions in partnership with the International Diabetes Federation European Region (IDF Europe).

19 Jun 2013

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia—low blood sugar—compared with the commercially available insulin glargine, a new meta-analysis study finds.

19 Jun 2013

AACE applauds the American Medical Association for recognizing obesity as disease state

The American Association of Clinical Endocrinologists (AACE) applauds the American Medical Association (AMA) House of Delegates for its action today to approve a resolution recognizing obesity as a disease state requiring a range of interventions to advance obesity treatment and prevention. AACE, the sponsor of the resolution, was joined by specialty and state medical societies in advocating for recognition of obesity as a disease state, including The Endocrine Society, American College of Cardiology, American College of Surgeons, American Urological Association, and the Texas State Delegation among many others.

19 Jun 2013

Risk assessment scoring system may help identify adults at risk of developing type 2 diabetes

Researchers have developed a risk assessment scoring system that they believe may better identify certain adults-- especially African Americans-- at high risk of developing type 2 diabetes, heart disease and stroke than does the current system of diagnosing the metabolic syndrome.

19 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

Study finds similar genetic variations in overweight newborns, obese adults

Similar genetic variations occur in both overweight newborns and obese adults, a large study finds.

19 Jun 2013

Combination of obesity and low testosterone increases risk of diabetes and brain damage

Low testosterone worsens the harmful effects of obesity in the nervous system, a new study in mice finds. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Obesity in adolescents is associated with sensorineural hearing loss

Obese adolescents are more likely than their normal-weight counterparts to have hearing loss, according to results of a new study. Findings showed that obese adolescents had increased hearing loss across all frequencies and were almost twice as likely to have unilateral (one-sided) low-frequency hearing loss.

18 Jun 2013

Overweight women who skip breakfast experience acute insulin resistance

Overweight women who skip breakfast experience acute, or rapid-onset, insulin resistance, a condition that, when chronic, is a risk factor for diabetes, a new study finds. The results, which were presented Sunday at The Endocrine Society's 95th Annual Meeting in San Francisco, suggest that regularly skipping breakfast over time may lead to chronic insulin resistance and thus could increase an individual's risk for type 2 diabetes.

18 Jun 2013

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 adults with type 2 diabetes to take part in the local arm of a major national clinical trial that will compare benefits and side effects of four widely used therapies to lower blood-sugar levels.

18 Jun 2013

Increasing red meat intake boosts risk of type-2 diabetes mellitus

Eating more red meat over time is associated with an increased risk of type-2 diabetes mellitus (T2DM) in a follow-up of three studies of about 149,000 U.S. men and women, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

18 Jun 2013

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Study: Multiple islet autoantibodies in children indicate risk of developing type 1 diabetes

Loyola researcher to study role of Vitamin D in women with diabetes and depression

GSMA announces first-of-its-kind clinical study for its mHealth Grand Tour

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

AACE applauds the American Medical Association for recognizing obesity as disease state

Risk assessment scoring system may help identify adults at risk of developing type 2 diabetes

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Study finds similar genetic variations in overweight newborns, obese adults

Combination of obesity and low testosterone increases risk of diabetes and brain damage

Obesity in adolescents is associated with sensorineural hearing loss

Overweight women who skip breakfast experience acute insulin resistance

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Increasing red meat intake boosts risk of type-2 diabetes mellitus

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in